Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man
Identifieur interne : 001444 ( Istex/Corpus ); précédent : 001443; suivant : 001445Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man
Auteurs : R. Raisman-Vozari ; J.-A. Girault ; S. Moussaoui ; C. Feuerstein ; P. Jenner ; C. D. Marsden ; Y. AgidSource :
- Brain Research [ 0006-8993 ] ; 1990.
English descriptors
- KwdEn :
Abstract
Abstract: The present study was performed to determine the effect of a nearly complete nigrostriatal dopaminergic denervation on DARPP-32 levels in the striatum from animals and parkinsonian patients. DARPP-32 levels were estimated by in vitro phosphorylation in the presence of cAMP, or after inactivation of endogenous kinases and phosphatases, in the presence of the catalytic subunit of cAMP-dependent protein kinase. Intranigral 6-hydroxydopamine (6-OHDA) infusion in rats, or peripheral administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets, did not change striatal DARPP-32 levels. Postmortem studies, carried out on brains obtained shortly after death, from patients with Parkinson disease, or from patients with progressive supranuclear palsy, showed that the levels of striatal DARPP-32 were not different from controls. These results indicate that dopaminergic striatal denervation did not modify the amount of DARPP-32 in the striatum, suggesting that the expression of DARPP-32, a protein which mediates some of the effects of dopamine in striatal neurons, is independent from the dopaminergic innervation.
Url:
DOI: 10.1016/0006-8993(90)90520-L
Links to Exploration step
ISTEX:FE34E2B9547A365626A3AD65A8E4BEAA74087A3BLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man</title>
<author><name sortKey="Raisman Vozari, R" sort="Raisman Vozari, R" uniqKey="Raisman Vozari R" first="R." last="Raisman-Vozari">R. Raisman-Vozari</name>
<affiliation><mods:affiliation>INSERM U 289, CHU Pitie´-Salpeˆtrie`re, Paris France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Girault, J A" sort="Girault, J A" uniqKey="Girault J" first="J.-A." last="Girault">J.-A. Girault</name>
<affiliation><mods:affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10021 U.S.A.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Moussaoui, S" sort="Moussaoui, S" uniqKey="Moussaoui S" first="S." last="Moussaoui">S. Moussaoui</name>
<affiliation><mods:affiliation>INSERM U 318, Laboratoire de Physiologie, Section Neurophysiologie, De´partement des Neurosciences Cliniques et Biologiques, CHU de Grenoble, Grenoble France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Feuerstein, C" sort="Feuerstein, C" uniqKey="Feuerstein C" first="C." last="Feuerstein">C. Feuerstein</name>
<affiliation><mods:affiliation>INSERM U 318, Laboratoire de Physiologie, Section Neurophysiologie, De´partement des Neurosciences Cliniques et Biologiques, CHU de Grenoble, Grenoble France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name>
<affiliation><mods:affiliation>Parkinson's Disease Society Research Center, University Department of Neurology, Institute of Psychiatry and King's College Hospital Medical School, London U.K.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
<affiliation><mods:affiliation>Parkinson's Disease Society Research Center, University Department of Neurology, Institute of Psychiatry and King's College Hospital Medical School, London U.K.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation><mods:affiliation>INSERM U 289, CHU Pitie´-Salpeˆtrie`re, Paris France</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:FE34E2B9547A365626A3AD65A8E4BEAA74087A3B</idno>
<date when="1990" year="1990">1990</date>
<idno type="doi">10.1016/0006-8993(90)90520-L</idno>
<idno type="url">https://api.istex.fr/document/FE34E2B9547A365626A3AD65A8E4BEAA74087A3B/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001444</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001444</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man</title>
<author><name sortKey="Raisman Vozari, R" sort="Raisman Vozari, R" uniqKey="Raisman Vozari R" first="R." last="Raisman-Vozari">R. Raisman-Vozari</name>
<affiliation><mods:affiliation>INSERM U 289, CHU Pitie´-Salpeˆtrie`re, Paris France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Girault, J A" sort="Girault, J A" uniqKey="Girault J" first="J.-A." last="Girault">J.-A. Girault</name>
<affiliation><mods:affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10021 U.S.A.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Moussaoui, S" sort="Moussaoui, S" uniqKey="Moussaoui S" first="S." last="Moussaoui">S. Moussaoui</name>
<affiliation><mods:affiliation>INSERM U 318, Laboratoire de Physiologie, Section Neurophysiologie, De´partement des Neurosciences Cliniques et Biologiques, CHU de Grenoble, Grenoble France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Feuerstein, C" sort="Feuerstein, C" uniqKey="Feuerstein C" first="C." last="Feuerstein">C. Feuerstein</name>
<affiliation><mods:affiliation>INSERM U 318, Laboratoire de Physiologie, Section Neurophysiologie, De´partement des Neurosciences Cliniques et Biologiques, CHU de Grenoble, Grenoble France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name>
<affiliation><mods:affiliation>Parkinson's Disease Society Research Center, University Department of Neurology, Institute of Psychiatry and King's College Hospital Medical School, London U.K.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
<affiliation><mods:affiliation>Parkinson's Disease Society Research Center, University Department of Neurology, Institute of Psychiatry and King's College Hospital Medical School, London U.K.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation><mods:affiliation>INSERM U 289, CHU Pitie´-Salpeˆtrie`re, Paris France</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Brain Research</title>
<title level="j" type="abbrev">BRES</title>
<idno type="ISSN">0006-8993</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1990">1990</date>
<biblScope unit="volume">507</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="45">45</biblScope>
<biblScope unit="page" to="50">50</biblScope>
</imprint>
<idno type="ISSN">0006-8993</idno>
</series>
<idno type="istex">FE34E2B9547A365626A3AD65A8E4BEAA74087A3B</idno>
<idno type="DOI">10.1016/0006-8993(90)90520-L</idno>
<idno type="PII">0006-8993(90)90520-L</idno>
<idno type="ArticleID">9090520L</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0006-8993</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
<term>DARPP-32</term>
<term>Dopaminergic lesion</term>
<term>Parkinson</term>
<term>Phosphoprotein</term>
<term>Striatum</term>
<term>Tyrosine hydroxylase</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: The present study was performed to determine the effect of a nearly complete nigrostriatal dopaminergic denervation on DARPP-32 levels in the striatum from animals and parkinsonian patients. DARPP-32 levels were estimated by in vitro phosphorylation in the presence of cAMP, or after inactivation of endogenous kinases and phosphatases, in the presence of the catalytic subunit of cAMP-dependent protein kinase. Intranigral 6-hydroxydopamine (6-OHDA) infusion in rats, or peripheral administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets, did not change striatal DARPP-32 levels. Postmortem studies, carried out on brains obtained shortly after death, from patients with Parkinson disease, or from patients with progressive supranuclear palsy, showed that the levels of striatal DARPP-32 were not different from controls. These results indicate that dopaminergic striatal denervation did not modify the amount of DARPP-32 in the striatum, suggesting that the expression of DARPP-32, a protein which mediates some of the effects of dopamine in striatal neurons, is independent from the dopaminergic innervation.</div>
</front>
</TEI>
<istex><corpusName>elsevier</corpusName>
<author><json:item><name>R. Raisman-Vozari</name>
<affiliations><json:string>INSERM U 289, CHU Pitie´-Salpeˆtrie`re, Paris France</json:string>
</affiliations>
</json:item>
<json:item><name>J.-A. Girault</name>
<affiliations><json:string>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10021 U.S.A.</json:string>
</affiliations>
</json:item>
<json:item><name>S. Moussaoui</name>
<affiliations><json:string>INSERM U 318, Laboratoire de Physiologie, Section Neurophysiologie, De´partement des Neurosciences Cliniques et Biologiques, CHU de Grenoble, Grenoble France</json:string>
</affiliations>
</json:item>
<json:item><name>C. Feuerstein</name>
<affiliations><json:string>INSERM U 318, Laboratoire de Physiologie, Section Neurophysiologie, De´partement des Neurosciences Cliniques et Biologiques, CHU de Grenoble, Grenoble France</json:string>
</affiliations>
</json:item>
<json:item><name>P. Jenner</name>
<affiliations><json:string>Parkinson's Disease Society Research Center, University Department of Neurology, Institute of Psychiatry and King's College Hospital Medical School, London U.K.</json:string>
</affiliations>
</json:item>
<json:item><name>C.D. Marsden</name>
<affiliations><json:string>Parkinson's Disease Society Research Center, University Department of Neurology, Institute of Psychiatry and King's College Hospital Medical School, London U.K.</json:string>
</affiliations>
</json:item>
<json:item><name>Y. Agid</name>
<affiliations><json:string>INSERM U 289, CHU Pitie´-Salpeˆtrie`re, Paris France</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>DARPP-32</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Tyrosine hydroxylase</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Phosphoprotein</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Parkinson</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Striatum</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Dopaminergic lesion</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</value>
</json:item>
</subject>
<articleId><json:string>9090520L</json:string>
</articleId>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>Short communication</json:string>
</originalGenre>
<abstract>Abstract: The present study was performed to determine the effect of a nearly complete nigrostriatal dopaminergic denervation on DARPP-32 levels in the striatum from animals and parkinsonian patients. DARPP-32 levels were estimated by in vitro phosphorylation in the presence of cAMP, or after inactivation of endogenous kinases and phosphatases, in the presence of the catalytic subunit of cAMP-dependent protein kinase. Intranigral 6-hydroxydopamine (6-OHDA) infusion in rats, or peripheral administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets, did not change striatal DARPP-32 levels. Postmortem studies, carried out on brains obtained shortly after death, from patients with Parkinson disease, or from patients with progressive supranuclear palsy, showed that the levels of striatal DARPP-32 were not different from controls. These results indicate that dopaminergic striatal denervation did not modify the amount of DARPP-32 in the striatum, suggesting that the expression of DARPP-32, a protein which mediates some of the effects of dopamine in striatal neurons, is independent from the dopaminergic innervation.</abstract>
<qualityIndicators><score>6.908</score>
<pdfVersion>1.3</pdfVersion>
<pdfPageSize>591 x 814 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<keywordCount>7</keywordCount>
<abstractCharCount>1170</abstractCharCount>
<pdfWordCount>6093</pdfWordCount>
<pdfCharCount>25394</pdfCharCount>
<pdfPageCount>6</pdfPageCount>
<abstractWordCount>159</abstractWordCount>
</qualityIndicators>
<title>Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man</title>
<pii><json:string>0006-8993(90)90520-L</json:string>
</pii>
<refBibs><json:item><author><json:item><name>R. Cash</name>
</json:item>
<json:item><name>R. Raisman</name>
</json:item>
<json:item><name>P. Cervera</name>
</json:item>
<json:item><name>F. Javoy-Agid</name>
</json:item>
<json:item><name>Y. Agid</name>
</json:item>
</author>
<host><volume>1</volume>
<pages><last>554</last>
<first>527</first>
</pages>
<author></author>
<title>J. Receptor Res.</title>
</host>
<title>Pitfalls in membrane binding sites studies in postmortem human brain</title>
</json:item>
<json:item><author><json:item><name>R. Cash</name>
</json:item>
<json:item><name>R. Raisman</name>
</json:item>
<json:item><name>A. Ploska</name>
</json:item>
<json:item><name>Y. Agid</name>
</json:item>
</author>
<host><volume>49</volume>
<pages><last>1083</last>
<first>1075</first>
</pages>
<author></author>
<title>J. Neurochem.</title>
</host>
<title>Dopamine D1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's disease</title>
</json:item>
<json:item><author><json:item><name>J.-A. Girault</name>
</json:item>
<json:item><name>R. Raisman</name>
</json:item>
<json:item><name>Y. Agid</name>
</json:item>
<json:item><name>P. Greengard</name>
</json:item>
</author>
<host><author></author>
<title>Proc. Natl. Acad. Sci. U.S.A.</title>
</host>
<serie><author></author>
<title>Proc. Natl. Acad. Sci. U.S.A.</title>
</serie>
<title>Striatal phosphoproteins in Parkinson disease and progressive supranuclear palsy</title>
</json:item>
<json:item><author><json:item><name>H.C. Hemmings, Jr.</name>
</json:item>
<json:item><name>A.C. Nairn</name>
</json:item>
<json:item><name>D.W. Aswaad</name>
</json:item>
<json:item><name>P. Greengard</name>
</json:item>
</author>
<host><volume>4</volume>
<pages><last>110</last>
<first>99</first>
</pages>
<author></author>
<title>J. Neurosci.</title>
</host>
<title>DARPP-32, a dopamine and adenosine3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine innervated brain regions. II. Purification and characterization of the phosphoprotein from bovine caudate nucleus</title>
</json:item>
<json:item><author><json:item><name>H.C. Hemmings, Jr.</name>
</json:item>
<json:item><name>P. Greengard</name>
</json:item>
</author>
<host><volume>6</volume>
<pages><last>1481</last>
<first>1469</first>
</pages>
<author></author>
<title>J. Neurosci.</title>
</host>
<title>DARPP-32, a dopamine and adenosine3′:5′-monophosphate-regulated phosphoprotein: regional, tissue and phylogenetic distribution</title>
</json:item>
<json:item><author><json:item><name>O. Hornykiewicz</name>
</json:item>
</author>
<host><volume>18</volume>
<pages><last>964</last>
<first>925</first>
</pages>
<author></author>
<title>Pharmacol. Rev.</title>
</host>
<title>Dopamine (3-hydroxytryptamine) and brain function</title>
</json:item>
<json:item><author><json:item><name>F. Javoy-Agid</name>
</json:item>
<json:item><name>A. Ploska</name>
</json:item>
<json:item><name>Y. Agid</name>
</json:item>
</author>
<host><volume>37</volume>
<pages><last>1227</last>
<first>1218</first>
</pages>
<author></author>
<title>J. Neurochem.</title>
</host>
<title>Microtopography of tyrosine hydroxylase, glutamic acid decar☐ylase and choline acetyltransferase in the substantia nigra and ventral tegmental area of control and parkinsonian brains</title>
</json:item>
<json:item><author><json:item><name>K. Jellinger</name>
</json:item>
</author>
<host><pages><last>165</last>
<first>124</first>
</pages>
<author></author>
<title>Movement Disorders</title>
</host>
<title>The pathology of parkinsonism</title>
</json:item>
<json:item><author><json:item><name>P. Jenner</name>
</json:item>
<json:item><name>N.M.J. Rupniak</name>
</json:item>
<json:item><name>S. Rose</name>
</json:item>
<json:item><name>R. Kelly</name>
</json:item>
<json:item><name>A. Lees</name>
</json:item>
<json:item><name>C.D. Marsden</name>
</json:item>
</author>
<host><volume>50</volume>
<pages><last>90</last>
<first>85</first>
</pages>
<author></author>
<title>Neurosci. Lett.</title>
</host>
<title>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset</title>
</json:item>
<json:item><author><json:item><name>T.H. Joh</name>
</json:item>
<json:item><name>D.H. Park</name>
</json:item>
<json:item><name>D.J. Reis</name>
</json:item>
</author>
<host><author></author>
<title>Proc. Natl. Acad. Sci. U.S.A.</title>
</host>
<serie><author></author>
<title>Proc. Natl. Acad. Sci. U.S.A.</title>
</serie>
<title>Direct phosphorylation of brain tyrosine hydroxylase by cyclic AMP-dependent protein kinase: mechanism of enzyme activation</title>
</json:item>
<json:item><author><json:item><name>J.W. Kebabian</name>
</json:item>
<json:item><name>D.B. Calne</name>
</json:item>
</author>
<host><volume>277</volume>
<pages><last>96</last>
<first>93</first>
</pages>
<author></author>
<title>Nature (Lond.)</title>
</host>
<title>Multiple receptors for dopamine</title>
</json:item>
<json:item><author><json:item><name>U.K. Laemmli</name>
</json:item>
</author>
<host><volume>227</volume>
<pages><last>685</last>
<first>680</first>
</pages>
<author></author>
<title>Nature (Lond.)</title>
</host>
<title>Cleavage of structural proteins during the assembly of the head of bacteriophage T4</title>
</json:item>
<json:item><author><json:item><name>J.W. Langston</name>
</json:item>
<json:item><name>P. Ballard</name>
</json:item>
<json:item><name>J.W. Tetrud</name>
</json:item>
<json:item><name>I. Irwinn</name>
</json:item>
</author>
<host><volume>219</volume>
<pages><last>980</last>
<first>979</first>
</pages>
<author></author>
<title>Science</title>
</host>
<title>Chronic parkinsonism in humans due to a product of meperidine-analog synthesis</title>
</json:item>
<json:item><author><json:item><name>O.H. Lowry</name>
</json:item>
<json:item><name>N.L. Rosebrough</name>
</json:item>
<json:item><name>A.L. Farr</name>
</json:item>
<json:item><name>R.J. Randall</name>
</json:item>
</author>
<host><volume>193</volume>
<pages><last>275</last>
<first>265</first>
</pages>
<author></author>
<title>J. Biol. Chem.</title>
</host>
<title>Protein measurement with the Folin phenol reagent</title>
</json:item>
<json:item><author><json:item><name>E. Melamed</name>
</json:item>
</author>
<host><author></author>
<title>Handbook of Parkinson's Disease</title>
</host>
<serie><author></author>
<title>Handbook of Parkinson's Disease</title>
</serie>
<title>Mechanism of action of levodopa</title>
</json:item>
<json:item><author><json:item><name>J.C. Monfort</name>
</json:item>
<json:item><name>F. Javoy-Agid</name>
</json:item>
<json:item><name>J.-J. Hauw</name>
</json:item>
<json:item><name>B. Dubois</name>
</json:item>
<json:item><name>Y. Agid</name>
</json:item>
</author>
<host><volume>108</volume>
<pages><last>313</last>
<first>301</first>
</pages>
<author></author>
<title>Brain</title>
</host>
<title>Brain glutamate decar☐ylase in Parkinson's disease with particular reference to premortem severity index</title>
</json:item>
<json:item><author><json:item><name>A.C. Nairn</name>
</json:item>
<json:item><name>H.C. Hemmings, Jr.</name>
</json:item>
<json:item><name>P. Greengard</name>
</json:item>
</author>
<host><volume>54</volume>
<pages><last>976</last>
<first>931</first>
</pages>
<author></author>
<title>Annu. Rev. Biochem.</title>
</host>
<title>Protein kinases in the brain</title>
</json:item>
<json:item><author><json:item><name>E.J. Nestler</name>
</json:item>
<json:item><name>S.I. Walaas</name>
</json:item>
<json:item><name>P. Greengard</name>
</json:item>
</author>
<host><volume>225</volume>
<pages><last>1364</last>
<first>1357</first>
</pages>
<author></author>
<title>Science</title>
</host>
<title>Neuronal phosphoproteins: physiological and clinical implications</title>
</json:item>
<json:item><author><json:item><name>Ch. Ouimet</name>
</json:item>
<json:item><name>P.E. Miller</name>
</json:item>
<json:item><name>H.C. Hemmings, Jr.</name>
</json:item>
<json:item><name>S.I. Walaas</name>
</json:item>
<json:item><name>P. Greengard</name>
</json:item>
</author>
<host><volume>4</volume>
<pages><last>124</last>
<first>111</first>
</pages>
<author></author>
<title>J. Neurosci.</title>
</host>
<title>DARPP-32, a dopamine and adenosine3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization</title>
</json:item>
<json:item><author><json:item><name>K. Oyanagi</name>
</json:item>
<json:item><name>H. Takahashi</name>
</json:item>
<json:item><name>K. Wakabayashi</name>
</json:item>
<json:item><name>F. Ikuta</name>
</json:item>
</author>
<host><volume>458</volume>
<pages><last>223</last>
<first>218</first>
</pages>
<author></author>
<title>Brain Research</title>
</host>
<title>Selective decrease of large neurons in the neostriatum in progressive supranuclear palsy</title>
</json:item>
<json:item><author><json:item><name>L. Pierrot</name>
</json:item>
<json:item><name>C. Desnos</name>
</json:item>
<json:item><name>J. Blin</name>
</json:item>
<json:item><name>R. Raisman</name>
</json:item>
<json:item><name>D. Sherman</name>
</json:item>
<json:item><name>F. Javoy-Agid</name>
</json:item>
<json:item><name>M. Ruberg</name>
</json:item>
<json:item><name>Y. Agid</name>
</json:item>
</author>
<host><volume>86</volume>
<pages><last>306</last>
<first>291</first>
</pages>
<author></author>
<title>J. Neurol. Sci.</title>
</host>
<title>D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy</title>
</json:item>
<json:item><author><json:item><name>J. Puymirat</name>
</json:item>
<json:item><name>F. Javoy-Agid</name>
</json:item>
<json:item><name>P. Gaspar</name>
</json:item>
<json:item><name>A. Ploska</name>
</json:item>
<json:item><name>A. Prochiantz</name>
</json:item>
<json:item><name>Y. Agid</name>
</json:item>
</author>
<host><volume>32</volume>
<pages><last>454</last>
<first>449</first>
</pages>
<author></author>
<title>J. Neurochem.</title>
</host>
<title>Postmortem stability and storage in the cold of brain enzymes</title>
</json:item>
<json:item><author><json:item><name>M. Ruberg</name>
</json:item>
<json:item><name>F. Javoy-Agid</name>
</json:item>
<json:item><name>E. Hirsh</name>
</json:item>
<json:item><name>B. Scatton</name>
</json:item>
<json:item><name>R. L'Heureux</name>
</json:item>
<json:item><name>J.-J. Hauw</name>
</json:item>
<json:item><name>C. Huyckaerts</name>
</json:item>
<json:item><name>F. Gray</name>
</json:item>
<json:item><name>A. Morel-Maroger</name>
</json:item>
<json:item><name>A. Rascol</name>
</json:item>
<json:item><name>M. Serdaru</name>
</json:item>
<json:item><name>Y. Agid</name>
</json:item>
</author>
<host><volume>18</volume>
<pages><last>529</last>
<first>523</first>
</pages>
<author></author>
<title>Ann. Neurol.</title>
</host>
<title>Dopaminergic and cholinergic lesions in progressive supranuclear palsy</title>
</json:item>
<json:item><author><json:item><name>J.M. Saavedra</name>
</json:item>
<json:item><name>P. Setler</name>
</json:item>
<json:item><name>J. Kebabian</name>
</json:item>
</author>
<host><volume>151</volume>
<pages><last>352</last>
<first>339</first>
</pages>
<author></author>
<title>Brain Research</title>
</host>
<title>Biochemical changes accompanying unilateral 6-hydroxydopamine lesions in the rat substantia nigra</title>
</json:item>
<json:item><author><json:item><name>L. Semerdjian-Rouquier</name>
</json:item>
<json:item><name>L. Bossi</name>
</json:item>
<json:item><name>B. Scatton</name>
</json:item>
</author>
<host><volume>218</volume>
<pages><last>670</last>
<first>663</first>
</pages>
<author></author>
<title>J. Chromatogr.</title>
</host>
<title>Determination of 5-hydroxytryptophan, serotonin and 5-hydroxyindoleacetic acid in rat and human brain and biological fluids by reverse-phase high-performance liquid chromatography with electrochemical detection</title>
</json:item>
<json:item><author><json:item><name>R.S. Sloviter</name>
</json:item>
<json:item><name>J.D. Connor</name>
</json:item>
</author>
<host><volume>28</volume>
<pages><last>1131</last>
<first>1129</first>
</pages>
<author></author>
<title>J. Neurochem.</title>
</host>
<title>Post mortem stability of norepinephrine, dopamine and serotonin in rat brain</title>
</json:item>
<json:item><author><json:item><name>J.C. Steele</name>
</json:item>
</author>
<host><volume>95</volume>
<pages><last>704</last>
<first>693</first>
</pages>
<author></author>
<title>Brain</title>
</host>
<title>Progressive supranuclear palsy</title>
</json:item>
<json:item><author><json:item><name>J.C. Stoof</name>
</json:item>
<json:item><name>J.W. Kebabian</name>
</json:item>
</author>
<host><volume>250</volume>
<pages><last>266</last>
<first>263</first>
</pages>
<author></author>
<title>Brain Research</title>
</host>
<title>Independent in vitro regulation by the D2 dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K+-stimulated release of acetylcholine from rat striatum</title>
</json:item>
<json:item><author><json:item><name>H. Towbin</name>
</json:item>
<json:item><name>T. Staehelin</name>
</json:item>
<json:item><name>J. Gordon</name>
</json:item>
</author>
<host><author></author>
<title>Proc. Natl. Acad. Sci. U.S.A.</title>
</host>
<serie><author></author>
<title>Proc. Natl. Acad. Sci. U.S.A.</title>
</serie>
<title>Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications</title>
</json:item>
<json:item><author><json:item><name>U. Ungerstedt</name>
</json:item>
</author>
<host><volume>367</volume>
<pages><last>122</last>
<first>69</first>
</pages>
<author></author>
<title>Acta Physiol. Scand.</title>
</host>
<title>Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system</title>
</json:item>
<json:item><author><json:item><name>S.I. Walaas</name>
</json:item>
<json:item><name>D.W. Aswaad</name>
</json:item>
<json:item><name>P. Greengard</name>
</json:item>
</author>
<host><volume>301</volume>
<pages><last>71</last>
<first>69</first>
</pages>
<author></author>
<title>Nature (Lond.)</title>
</host>
<title>A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions</title>
</json:item>
<json:item><author><json:item><name>S.I. Walaas</name>
</json:item>
<json:item><name>P. Greengard</name>
</json:item>
</author>
<host><volume>4</volume>
<pages><last>98</last>
<first>84</first>
</pages>
<author></author>
<title>J. Neurosci.</title>
</host>
<title>DARPP-32, a dopamine and adenosine3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. I. Regional and cellular distribution in the rat brain</title>
</json:item>
<json:item><author><json:item><name>F.A. Wiesel</name>
</json:item>
<json:item><name>G. Sedvall</name>
</json:item>
</author>
<host><volume>65</volume>
<pages><last>550</last>
<first>547</first>
</pages>
<author></author>
<title>Brain Research</title>
</host>
<title>Post mortal changes of dopamine and homovanillic acid levels in rat striatum as measured by mass fragmentography</title>
</json:item>
<json:item><author><json:item><name>B. Zivcovic</name>
</json:item>
<json:item><name>A. Guidotti</name>
</json:item>
<json:item><name>E. Costa</name>
</json:item>
</author>
<host><volume>10</volume>
<pages><last>735</last>
<first>725</first>
</pages>
<author></author>
<title>Mol. Pharmacol.</title>
</host>
<title>Effect of neuroleptics on striatal tyrosine hydroxylase: changes in the affinity for the pteridine cofactor</title>
</json:item>
</refBibs>
<genre><json:string>brief-communication</json:string>
</genre>
<serie><volume>89</volume>
<pages><last>2497</last>
<first>2493</first>
</pages>
<language><json:string>unknown</json:string>
</language>
<title>Proc. Natl. Acad. Sci. U.S.A.</title>
</serie>
<host><volume>507</volume>
<pii><json:string>S0006-8993(00)X0534-3</json:string>
</pii>
<pages><last>50</last>
<first>45</first>
</pages>
<issn><json:string>0006-8993</json:string>
</issn>
<issue>1</issue>
<genre><json:string>journal</json:string>
</genre>
<language><json:string>unknown</json:string>
</language>
<title>Brain Research</title>
<publicationDate>1990</publicationDate>
</host>
<categories><wos><json:string>science</json:string>
<json:string>neurosciences</json:string>
</wos>
<scienceMetrix><json:string>health sciences</json:string>
<json:string>clinical medicine</json:string>
<json:string>neurology & neurosurgery</json:string>
</scienceMetrix>
</categories>
<publicationDate>1990</publicationDate>
<copyrightDate>1990</copyrightDate>
<doi><json:string>10.1016/0006-8993(90)90520-L</json:string>
</doi>
<id>FE34E2B9547A365626A3AD65A8E4BEAA74087A3B</id>
<score>0.12927194</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/FE34E2B9547A365626A3AD65A8E4BEAA74087A3B/fulltext/pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/FE34E2B9547A365626A3AD65A8E4BEAA74087A3B/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/FE34E2B9547A365626A3AD65A8E4BEAA74087A3B/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>ELSEVIER</publisher>
<availability><p>©1990 Elsevier Science Publishers B.V.</p>
</availability>
<date>1990</date>
</publicationStmt>
<sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man</title>
<author xml:id="author-1"><persName><forename type="first">R.</forename>
<surname>Raisman-Vozari</surname>
</persName>
<note type="correspondence"><p>Correspondence: R. Raisman, Laboratoire de Me´decine Expe´rimentale, INSERM U 289, Hoˆpital de la Salpeˆtrie`re, 47 boulevard de l'Hoˆpital, 75651 Paris Cedex 13, France.</p>
</note>
<affiliation>INSERM U 289, CHU Pitie´-Salpeˆtrie`re, Paris France</affiliation>
</author>
<author xml:id="author-2"><persName><forename type="first">J.-A.</forename>
<surname>Girault</surname>
</persName>
<affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10021 U.S.A.</affiliation>
</author>
<author xml:id="author-3"><persName><forename type="first">S.</forename>
<surname>Moussaoui</surname>
</persName>
<affiliation>INSERM U 318, Laboratoire de Physiologie, Section Neurophysiologie, De´partement des Neurosciences Cliniques et Biologiques, CHU de Grenoble, Grenoble France</affiliation>
</author>
<author xml:id="author-4"><persName><forename type="first">C.</forename>
<surname>Feuerstein</surname>
</persName>
<affiliation>INSERM U 318, Laboratoire de Physiologie, Section Neurophysiologie, De´partement des Neurosciences Cliniques et Biologiques, CHU de Grenoble, Grenoble France</affiliation>
</author>
<author xml:id="author-5"><persName><forename type="first">P.</forename>
<surname>Jenner</surname>
</persName>
<affiliation>Parkinson's Disease Society Research Center, University Department of Neurology, Institute of Psychiatry and King's College Hospital Medical School, London U.K.</affiliation>
</author>
<author xml:id="author-6"><persName><forename type="first">C.D.</forename>
<surname>Marsden</surname>
</persName>
<affiliation>Parkinson's Disease Society Research Center, University Department of Neurology, Institute of Psychiatry and King's College Hospital Medical School, London U.K.</affiliation>
</author>
<author xml:id="author-7"><persName><forename type="first">Y.</forename>
<surname>Agid</surname>
</persName>
<affiliation>INSERM U 289, CHU Pitie´-Salpeˆtrie`re, Paris France</affiliation>
</author>
</analytic>
<monogr><title level="j">Brain Research</title>
<title level="j" type="abbrev">BRES</title>
<idno type="pISSN">0006-8993</idno>
<idno type="PII">S0006-8993(00)X0534-3</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1990"></date>
<biblScope unit="volume">507</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="45">45</biblScope>
<biblScope unit="page" to="50">50</biblScope>
</imprint>
</monogr>
<idno type="istex">FE34E2B9547A365626A3AD65A8E4BEAA74087A3B</idno>
<idno type="DOI">10.1016/0006-8993(90)90520-L</idno>
<idno type="PII">0006-8993(90)90520-L</idno>
<idno type="ArticleID">9090520L</idno>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><creation><date>1990</date>
</creation>
<langUsage><language ident="en">en</language>
</langUsage>
<abstract xml:lang="en"><p>Abstract: The present study was performed to determine the effect of a nearly complete nigrostriatal dopaminergic denervation on DARPP-32 levels in the striatum from animals and parkinsonian patients. DARPP-32 levels were estimated by in vitro phosphorylation in the presence of cAMP, or after inactivation of endogenous kinases and phosphatases, in the presence of the catalytic subunit of cAMP-dependent protein kinase. Intranigral 6-hydroxydopamine (6-OHDA) infusion in rats, or peripheral administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets, did not change striatal DARPP-32 levels. Postmortem studies, carried out on brains obtained shortly after death, from patients with Parkinson disease, or from patients with progressive supranuclear palsy, showed that the levels of striatal DARPP-32 were not different from controls. These results indicate that dopaminergic striatal denervation did not modify the amount of DARPP-32 in the striatum, suggesting that the expression of DARPP-32, a protein which mediates some of the effects of dopamine in striatal neurons, is independent from the dopaminergic innervation.</p>
</abstract>
<textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head>
<item><term>DARPP-32</term>
</item>
<item><term>Tyrosine hydroxylase</term>
</item>
<item><term>Phosphoprotein</term>
</item>
<item><term>Parkinson</term>
</item>
<item><term>Striatum</term>
</item>
<item><term>Dopaminergic lesion</term>
</item>
<item><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
</item>
</list>
</keywords>
</textClass>
</profileDesc>
<revisionDesc><change when="1990">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/FE34E2B9547A365626A3AD65A8E4BEAA74087A3B/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Elsevier doc found" wicri:toSee="Elsevier, no converted or simple article"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration>
<istex:docType PUBLIC="-//ES//DTD journal article DTD version 5.0.1//EN//XML" URI="art501.dtd" name="istex:docType"></istex:docType>
<istex:document><article version="5.0" xml:lang="en" docsubtype="sco"><item-info><jid>BRES</jid>
<aid>9090520L</aid>
<ce:pii>0006-8993(90)90520-L</ce:pii>
<ce:doi>10.1016/0006-8993(90)90520-L</ce:doi>
<ce:copyright type="unknown" year="1990">Elsevier Science Publishers B.V.</ce:copyright>
</item-info>
<head><ce:title>Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man</ce:title>
<ce:author-group><ce:author><ce:given-name>R.</ce:given-name>
<ce:surname>Raisman-Vozari</ce:surname>
<ce:cross-ref refid="cor1"><ce:sup loc="post">*</ce:sup>
</ce:cross-ref>
<ce:cross-ref refid="aff1"><ce:sup loc="post">1</ce:sup>
</ce:cross-ref>
</ce:author>
<ce:author><ce:given-name>J.-A.</ce:given-name>
<ce:surname>Girault</ce:surname>
<ce:cross-ref refid="aff2"><ce:sup loc="post">2</ce:sup>
</ce:cross-ref>
</ce:author>
<ce:author><ce:given-name>S.</ce:given-name>
<ce:surname>Moussaoui</ce:surname>
<ce:cross-ref refid="aff3"><ce:sup loc="post">3</ce:sup>
</ce:cross-ref>
</ce:author>
<ce:author><ce:given-name>C.</ce:given-name>
<ce:surname>Feuerstein</ce:surname>
<ce:cross-ref refid="aff3"><ce:sup loc="post">3</ce:sup>
</ce:cross-ref>
</ce:author>
<ce:author><ce:given-name>P.</ce:given-name>
<ce:surname>Jenner</ce:surname>
<ce:cross-ref refid="aff4"><ce:sup loc="post">4</ce:sup>
</ce:cross-ref>
</ce:author>
<ce:author><ce:given-name>C.D.</ce:given-name>
<ce:surname>Marsden</ce:surname>
<ce:cross-ref refid="aff4"><ce:sup loc="post">4</ce:sup>
</ce:cross-ref>
</ce:author>
<ce:author><ce:given-name>Y.</ce:given-name>
<ce:surname>Agid</ce:surname>
<ce:cross-ref refid="aff1"><ce:sup loc="post">1</ce:sup>
</ce:cross-ref>
</ce:author>
<ce:affiliation id="aff1"><ce:label>a</ce:label>
<ce:textfn>INSERM U 289, CHU Pitie´-Salpeˆtrie`re, Paris France</ce:textfn>
</ce:affiliation>
<ce:affiliation id="aff2"><ce:label>b</ce:label>
<ce:textfn>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10021 U.S.A.</ce:textfn>
</ce:affiliation>
<ce:affiliation id="aff3"><ce:label>c</ce:label>
<ce:textfn>INSERM U 318, Laboratoire de Physiologie, Section Neurophysiologie, De´partement des Neurosciences Cliniques et Biologiques, CHU de Grenoble, Grenoble France</ce:textfn>
</ce:affiliation>
<ce:affiliation id="aff4"><ce:label>d</ce:label>
<ce:textfn>Parkinson's Disease Society Research Center, University Department of Neurology, Institute of Psychiatry and King's College Hospital Medical School, London U.K.</ce:textfn>
</ce:affiliation>
<ce:correspondence id="cor1"><ce:label>*</ce:label>
<ce:text><ce:italic>Correspondence:</ce:italic>
R. Raisman, Laboratoire de Me´decine Expe´rimentale, INSERM U 289, Hoˆpital de la Salpeˆtrie`re, 47 boulevard de l'Hoˆpital, 75651 Paris Cedex 13, France.</ce:text>
</ce:correspondence>
</ce:author-group>
<ce:date-accepted day="13" month="6" year="1989"></ce:date-accepted>
<ce:abstract id="ab1" class="author" xml:lang="en"><ce:section-title>Abstract</ce:section-title>
<ce:abstract-sec><ce:simple-para view="all" id="simple-para.0010">The present study was performed to determine the effect of a nearly complete nigrostriatal dopaminergic denervation on DARPP-32 levels in the striatum from animals and parkinsonian patients. DARPP-32 levels were estimated by in vitro phosphorylation in the presence of cAMP, or after inactivation of endogenous kinases and phosphatases, in the presence of the catalytic subunit of cAMP-dependent protein kinase. Intranigral 6-hydroxydopamine (6-OHDA) infusion in rats, or peripheral administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets, did not change striatal DARPP-32 levels. Postmortem studies, carried out on brains obtained shortly after death, from patients with Parkinson disease, or from patients with progressive supranuclear palsy, showed that the levels of striatal DARPP-32 were not different from controls. These results indicate that dopaminergic striatal denervation did not modify the amount of DARPP-32 in the striatum, suggesting that the expression of DARPP-32, a protein which mediates some of the effects of dopamine in striatal neurons, is independent from the dopaminergic innervation.</ce:simple-para>
</ce:abstract-sec>
</ce:abstract>
<ce:keywords class="keyword" xml:lang="en"><ce:section-title>Keywords</ce:section-title>
<ce:keyword><ce:text>DARPP-32</ce:text>
</ce:keyword>
<ce:keyword><ce:text>Tyrosine hydroxylase</ce:text>
</ce:keyword>
<ce:keyword><ce:text>Phosphoprotein</ce:text>
</ce:keyword>
<ce:keyword><ce:text>Parkinson</ce:text>
</ce:keyword>
<ce:keyword><ce:text>Striatum</ce:text>
</ce:keyword>
<ce:keyword><ce:text>Dopaminergic lesion</ce:text>
</ce:keyword>
<ce:keyword><ce:text>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</ce:text>
</ce:keyword>
</ce:keywords>
</head>
<tail view="all"><ce:bibliography view="all" id="bibliography.0010"><ce:section-title>Reference</ce:section-title>
<ce:bibliography-sec id="bibliography-sec.0010"><ce:bib-reference id="bib1"><ce:label>1</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Cash</ce:surname>
<ce:given-name>R.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Raisman</ce:surname>
<ce:given-name>R.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Cervera</ce:surname>
<ce:given-name>P.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Javoy-Agid</ce:surname>
<ce:given-name>F.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Agid</ce:surname>
<ce:given-name>Y.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Pitfalls in membrane binding sites studies in postmortem human brain</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Receptor Res.</sb:maintitle>
</sb:title>
<sb:volume-nr>1</sb:volume-nr>
</sb:series>
<sb:date>1987</sb:date>
</sb:issue>
<sb:pages><sb:first-page>527</sb:first-page>
<sb:last-page>554</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib2"><ce:label>2</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Cash</ce:surname>
<ce:given-name>R.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Raisman</ce:surname>
<ce:given-name>R.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Ploska</ce:surname>
<ce:given-name>A.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Agid</ce:surname>
<ce:given-name>Y.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Dopamine D<ce:inf loc="post">1</ce:inf>
receptor and cyclic AMP-dependent phosphorylation in Parkinson's disease</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurochem.</sb:maintitle>
</sb:title>
<sb:volume-nr>49</sb:volume-nr>
</sb:series>
<sb:date>1987</sb:date>
</sb:issue>
<sb:pages><sb:first-page>1075</sb:first-page>
<sb:last-page>1083</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib3"><ce:label>3</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Girault</ce:surname>
<ce:given-name>J.-A.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Raisman</ce:surname>
<ce:given-name>R.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Agid</ce:surname>
<ce:given-name>Y.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Greengard</ce:surname>
<ce:given-name>P.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Striatal phosphoproteins in Parkinson disease and progressive supranuclear palsy</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:edited-book><sb:edition>2nd edn.</sb:edition>
<sb:book-series><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
</sb:title>
<sb:volume-nr>89</sb:volume-nr>
</sb:series>
</sb:book-series>
<sb:date>1989</sb:date>
</sb:edited-book>
<sb:pages><sb:first-page>2493</sb:first-page>
<sb:last-page>2497</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib4"><ce:label>4</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Hemmings</ce:surname>
<ce:given-name>H.C.</ce:given-name>
<ce:suffix>Jr.</ce:suffix>
</sb:author>
<sb:author><ce:surname>Nairn</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Aswaad</ce:surname>
<ce:given-name>D.W.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Greengard</ce:surname>
<ce:given-name>P.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>DARPP-32, a dopamine and adenosine3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine innervated brain regions. II. Purification and characterization of the phosphoprotein from bovine caudate nucleus</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurosci.</sb:maintitle>
</sb:title>
<sb:volume-nr>4</sb:volume-nr>
</sb:series>
<sb:date>1984</sb:date>
</sb:issue>
<sb:pages><sb:first-page>99</sb:first-page>
<sb:last-page>110</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib5"><ce:label>5</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Hemmings</ce:surname>
<ce:given-name>H.C.</ce:given-name>
<ce:suffix>Jr.</ce:suffix>
</sb:author>
<sb:author><ce:surname>Greengard</ce:surname>
<ce:given-name>P.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>DARPP-32, a dopamine and adenosine3′:5′-monophosphate-regulated phosphoprotein: regional, tissue and phylogenetic distribution</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurosci.</sb:maintitle>
</sb:title>
<sb:volume-nr>6</sb:volume-nr>
</sb:series>
<sb:date>1986</sb:date>
</sb:issue>
<sb:pages><sb:first-page>1469</sb:first-page>
<sb:last-page>1481</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib6"><ce:label>6</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Hornykiewicz</ce:surname>
<ce:given-name>O.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Dopamine (3-hydroxytryptamine) and brain function</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Pharmacol. Rev.</sb:maintitle>
</sb:title>
<sb:volume-nr>18</sb:volume-nr>
</sb:series>
<sb:date>1966</sb:date>
</sb:issue>
<sb:pages><sb:first-page>925</sb:first-page>
<sb:last-page>964</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib7"><ce:label>7</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Javoy-Agid</ce:surname>
<ce:given-name>F.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Ploska</ce:surname>
<ce:given-name>A.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Agid</ce:surname>
<ce:given-name>Y.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Microtopography of tyrosine hydroxylase, glutamic acid decar☐ylase and choline acetyltransferase in the substantia nigra and ventral tegmental area of control and parkinsonian brains</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurochem.</sb:maintitle>
</sb:title>
<sb:volume-nr>37</sb:volume-nr>
</sb:series>
<sb:date>1981</sb:date>
</sb:issue>
<sb:pages><sb:first-page>1218</sb:first-page>
<sb:last-page>1227</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib8"><ce:label>8</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Jellinger</ce:surname>
<ce:given-name>K.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>The pathology of parkinsonism</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:edited-book><sb:editors><sb:editor><ce:surname>Marsden</ce:surname>
<ce:given-name>C.D.</ce:given-name>
</sb:editor>
<sb:editor><ce:surname>Fahn</ce:surname>
<ce:given-name>S.</ce:given-name>
</sb:editor>
</sb:editors>
<sb:title><sb:maintitle>Movement Disorders</sb:maintitle>
</sb:title>
<sb:edition>2nd edn.</sb:edition>
<sb:date>1987</sb:date>
</sb:edited-book>
<sb:pages><sb:first-page>124</sb:first-page>
<sb:last-page>165</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib9"><ce:label>9</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Jenner</ce:surname>
<ce:given-name>P.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Rupniak</ce:surname>
<ce:given-name>N.M.J.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Rose</ce:surname>
<ce:given-name>S.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Kelly</ce:surname>
<ce:given-name>R.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Lees</ce:surname>
<ce:given-name>A.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Marsden</ce:surname>
<ce:given-name>C.D.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurosci. Lett.</sb:maintitle>
</sb:title>
<sb:volume-nr>50</sb:volume-nr>
</sb:series>
<sb:date>1984</sb:date>
</sb:issue>
<sb:pages><sb:first-page>85</sb:first-page>
<sb:last-page>90</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib10"><ce:label>10</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Joh</ce:surname>
<ce:given-name>T.H.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Park</ce:surname>
<ce:given-name>D.H.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Reis</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Direct phosphorylation of brain tyrosine hydroxylase by cyclic AMP-dependent protein kinase: mechanism of enzyme activation</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:edited-book><sb:edition>2nd edn.</sb:edition>
<sb:book-series><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
</sb:title>
<sb:volume-nr>75</sb:volume-nr>
</sb:series>
</sb:book-series>
<sb:date>1978</sb:date>
</sb:edited-book>
<sb:pages><sb:first-page>4744</sb:first-page>
<sb:last-page>4748</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib11"><ce:label>11</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Kebabian</ce:surname>
<ce:given-name>J.W.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Calne</ce:surname>
<ce:given-name>D.B.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Multiple receptors for dopamine</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature (Lond.)</sb:maintitle>
</sb:title>
<sb:volume-nr>277</sb:volume-nr>
</sb:series>
<sb:date>1979</sb:date>
</sb:issue>
<sb:pages><sb:first-page>93</sb:first-page>
<sb:last-page>96</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib12"><ce:label>12</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Laemmli</ce:surname>
<ce:given-name>U.K.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Cleavage of structural proteins during the assembly of the head of bacteriophage T4</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature (Lond.)</sb:maintitle>
</sb:title>
<sb:volume-nr>227</sb:volume-nr>
</sb:series>
<sb:date>1970</sb:date>
</sb:issue>
<sb:pages><sb:first-page>680</sb:first-page>
<sb:last-page>685</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib13"><ce:label>13</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Langston</ce:surname>
<ce:given-name>J.W.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Ballard</ce:surname>
<ce:given-name>P.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Tetrud</ce:surname>
<ce:given-name>J.W.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Irwinn</ce:surname>
<ce:given-name>I.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Chronic parkinsonism in humans due to a product of meperidine-analog synthesis</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Science</sb:maintitle>
</sb:title>
<sb:volume-nr>219</sb:volume-nr>
</sb:series>
<sb:date>1983</sb:date>
</sb:issue>
<sb:pages><sb:first-page>979</sb:first-page>
<sb:last-page>980</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib14"><ce:label>14</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Lowry</ce:surname>
<ce:given-name>O.H.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Rosebrough</ce:surname>
<ce:given-name>N.L.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Farr</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Randall</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Protein measurement with the Folin phenol reagent</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle>
</sb:title>
<sb:volume-nr>193</sb:volume-nr>
</sb:series>
<sb:date>1951</sb:date>
</sb:issue>
<sb:pages><sb:first-page>265</sb:first-page>
<sb:last-page>275</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib15"><ce:label>15</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Melamed</ce:surname>
<ce:given-name>E.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Mechanism of action of levodopa</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:edited-book><sb:edition>2nd edn.</sb:edition>
<sb:book-series><sb:editors><sb:editor><ce:surname>Koller</ce:surname>
<ce:given-name>I.</ce:given-name>
</sb:editor>
<sb:editor><ce:surname>Williams</ce:surname>
<ce:given-name>C.</ce:given-name>
</sb:editor>
</sb:editors>
<sb:series><sb:title><sb:maintitle>Handbook of Parkinson's Disease</sb:maintitle>
</sb:title>
</sb:series>
</sb:book-series>
<sb:date>1987</sb:date>
<sb:publisher><sb:name>Dekker</sb:name>
</sb:publisher>
</sb:edited-book>
<sb:pages><sb:first-page>355</sb:first-page>
<sb:last-page>370</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib16"><ce:label>16</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Monfort</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Javoy-Agid</ce:surname>
<ce:given-name>F.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Hauw</ce:surname>
<ce:given-name>J.-J.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Dubois</ce:surname>
<ce:given-name>B.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Agid</ce:surname>
<ce:given-name>Y.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Brain glutamate decar☐ylase in Parkinson's disease with particular reference to premortem severity index</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain</sb:maintitle>
</sb:title>
<sb:volume-nr>108</sb:volume-nr>
</sb:series>
<sb:date>1985</sb:date>
</sb:issue>
<sb:pages><sb:first-page>301</sb:first-page>
<sb:last-page>313</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib17"><ce:label>17</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Nairn</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Hemmings</ce:surname>
<ce:given-name>H.C.</ce:given-name>
<ce:suffix>Jr.</ce:suffix>
</sb:author>
<sb:author><ce:surname>Greengard</ce:surname>
<ce:given-name>P.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Protein kinases in the brain</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Annu. Rev. Biochem.</sb:maintitle>
</sb:title>
<sb:volume-nr>54</sb:volume-nr>
</sb:series>
<sb:date>1985</sb:date>
</sb:issue>
<sb:pages><sb:first-page>931</sb:first-page>
<sb:last-page>976</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib18"><ce:label>18</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Nestler</ce:surname>
<ce:given-name>E.J.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Walaas</ce:surname>
<ce:given-name>S.I.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Greengard</ce:surname>
<ce:given-name>P.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Neuronal phosphoproteins: physiological and clinical implications</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Science</sb:maintitle>
</sb:title>
<sb:volume-nr>225</sb:volume-nr>
</sb:series>
<sb:date>1984</sb:date>
</sb:issue>
<sb:pages><sb:first-page>1357</sb:first-page>
<sb:last-page>1364</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib19"><ce:label>19</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Ouimet</ce:surname>
<ce:given-name>Ch.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Miller</ce:surname>
<ce:given-name>P.E.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Hemmings</ce:surname>
<ce:given-name>H.C.</ce:given-name>
<ce:suffix>Jr.</ce:suffix>
</sb:author>
<sb:author><ce:surname>Walaas</ce:surname>
<ce:given-name>S.I.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Greengard</ce:surname>
<ce:given-name>P.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>DARPP-32, a dopamine and adenosine3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurosci.</sb:maintitle>
</sb:title>
<sb:volume-nr>4</sb:volume-nr>
</sb:series>
<sb:date>1984</sb:date>
</sb:issue>
<sb:pages><sb:first-page>111</sb:first-page>
<sb:last-page>124</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib20"><ce:label>20</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Oyanagi</ce:surname>
<ce:given-name>K.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Takahashi</ce:surname>
<ce:given-name>H.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Wakabayashi</ce:surname>
<ce:given-name>K.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Ikuta</ce:surname>
<ce:given-name>F.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Selective decrease of large neurons in the neostriatum in progressive supranuclear palsy</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Research</sb:maintitle>
</sb:title>
<sb:volume-nr>458</sb:volume-nr>
</sb:series>
<sb:date>1988</sb:date>
</sb:issue>
<sb:pages><sb:first-page>218</sb:first-page>
<sb:last-page>223</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib21"><ce:label>21</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Pierrot</ce:surname>
<ce:given-name>L.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Desnos</ce:surname>
<ce:given-name>C.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Blin</ce:surname>
<ce:given-name>J.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Raisman</ce:surname>
<ce:given-name>R.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Sherman</ce:surname>
<ce:given-name>D.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Javoy-Agid</ce:surname>
<ce:given-name>F.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Ruberg</ce:surname>
<ce:given-name>M.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Agid</ce:surname>
<ce:given-name>Y.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>D<ce:inf loc="post">1</ce:inf>
and D<ce:inf loc="post">2</ce:inf>
-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurol. Sci.</sb:maintitle>
</sb:title>
<sb:volume-nr>86</sb:volume-nr>
</sb:series>
<sb:date>1988</sb:date>
</sb:issue>
<sb:pages><sb:first-page>291</sb:first-page>
<sb:last-page>306</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib22"><ce:label>22</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Puymirat</ce:surname>
<ce:given-name>J.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Javoy-Agid</ce:surname>
<ce:given-name>F.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Gaspar</ce:surname>
<ce:given-name>P.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Ploska</ce:surname>
<ce:given-name>A.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Prochiantz</ce:surname>
<ce:given-name>A.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Agid</ce:surname>
<ce:given-name>Y.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Postmortem stability and storage in the cold of brain enzymes</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurochem.</sb:maintitle>
</sb:title>
<sb:volume-nr>32</sb:volume-nr>
</sb:series>
<sb:date>1979</sb:date>
</sb:issue>
<sb:pages><sb:first-page>449</sb:first-page>
<sb:last-page>454</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib23"><ce:label>23</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Ruberg</ce:surname>
<ce:given-name>M.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Javoy-Agid</ce:surname>
<ce:given-name>F.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Hirsh</ce:surname>
<ce:given-name>E.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Scatton</ce:surname>
<ce:given-name>B.</ce:given-name>
</sb:author>
<sb:author><ce:surname>L'Heureux</ce:surname>
<ce:given-name>R.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Hauw</ce:surname>
<ce:given-name>J.-J.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Huyckaerts</ce:surname>
<ce:given-name>C.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Gray</ce:surname>
<ce:given-name>F.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Morel-Maroger</ce:surname>
<ce:given-name>A.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Rascol</ce:surname>
<ce:given-name>A.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Serdaru</ce:surname>
<ce:given-name>M.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Agid</ce:surname>
<ce:given-name>Y.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Dopaminergic and cholinergic lesions in progressive supranuclear palsy</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle>
</sb:title>
<sb:volume-nr>18</sb:volume-nr>
</sb:series>
<sb:date>1985</sb:date>
</sb:issue>
<sb:pages><sb:first-page>523</sb:first-page>
<sb:last-page>529</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib24"><ce:label>24</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Saavedra</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Setler</ce:surname>
<ce:given-name>P.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Kebabian</ce:surname>
<ce:given-name>J.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Biochemical changes accompanying unilateral 6-hydroxydopamine lesions in the rat substantia nigra</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Research</sb:maintitle>
</sb:title>
<sb:volume-nr>151</sb:volume-nr>
</sb:series>
<sb:date>1978</sb:date>
</sb:issue>
<sb:pages><sb:first-page>339</sb:first-page>
<sb:last-page>352</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib25"><ce:label>25</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Semerdjian-Rouquier</ce:surname>
<ce:given-name>L.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Bossi</ce:surname>
<ce:given-name>L.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Scatton</ce:surname>
<ce:given-name>B.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Determination of 5-hydroxytryptophan, serotonin and 5-hydroxyindoleacetic acid in rat and human brain and biological fluids by reverse-phase high-performance liquid chromatography with electrochemical detection</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Chromatogr.</sb:maintitle>
</sb:title>
<sb:volume-nr>218</sb:volume-nr>
</sb:series>
<sb:date>1981</sb:date>
</sb:issue>
<sb:pages><sb:first-page>663</sb:first-page>
<sb:last-page>670</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib26"><ce:label>26</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Sloviter</ce:surname>
<ce:given-name>R.S.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Connor</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Post mortem stability of norepinephrine, dopamine and serotonin in rat brain</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurochem.</sb:maintitle>
</sb:title>
<sb:volume-nr>28</sb:volume-nr>
</sb:series>
<sb:date>1977</sb:date>
</sb:issue>
<sb:pages><sb:first-page>1129</sb:first-page>
<sb:last-page>1131</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib27"><ce:label>27</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Steele</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Progressive supranuclear palsy</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain</sb:maintitle>
</sb:title>
<sb:volume-nr>95</sb:volume-nr>
</sb:series>
<sb:date>1972</sb:date>
</sb:issue>
<sb:pages><sb:first-page>693</sb:first-page>
<sb:last-page>704</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib28"><ce:label>28</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Stoof</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Kebabian</ce:surname>
<ce:given-name>J.W.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Independent in vitro regulation by the D<ce:inf loc="post">2</ce:inf>
dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K<ce:sup loc="post">+</ce:sup>
-stimulated release of acetylcholine from rat striatum</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Research</sb:maintitle>
</sb:title>
<sb:volume-nr>250</sb:volume-nr>
</sb:series>
<sb:date>1982</sb:date>
</sb:issue>
<sb:pages><sb:first-page>263</sb:first-page>
<sb:last-page>266</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib29"><ce:label>29</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Towbin</ce:surname>
<ce:given-name>H.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Staehelin</ce:surname>
<ce:given-name>T.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Gordon</ce:surname>
<ce:given-name>J.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:edited-book><sb:edition>2nd edn.</sb:edition>
<sb:book-series><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
</sb:title>
<sb:volume-nr>76</sb:volume-nr>
</sb:series>
</sb:book-series>
<sb:date>1979</sb:date>
</sb:edited-book>
<sb:pages><sb:first-page>4350</sb:first-page>
<sb:last-page>4354</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib30"><ce:label>30</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Ungerstedt</ce:surname>
<ce:given-name>U.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Acta Physiol. Scand.</sb:maintitle>
</sb:title>
<sb:volume-nr>367</sb:volume-nr>
</sb:series>
<sb:date>1971</sb:date>
</sb:issue>
<sb:pages><sb:first-page>69</sb:first-page>
<sb:last-page>122</sb:last-page>
</sb:pages>
</sb:host>
<sb:comment>Suppl.</sb:comment>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib31"><ce:label>31</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Walaas</ce:surname>
<ce:given-name>S.I.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Aswaad</ce:surname>
<ce:given-name>D.W.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Greengard</ce:surname>
<ce:given-name>P.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature (Lond.)</sb:maintitle>
</sb:title>
<sb:volume-nr>301</sb:volume-nr>
</sb:series>
<sb:date>1983</sb:date>
</sb:issue>
<sb:pages><sb:first-page>69</sb:first-page>
<sb:last-page>71</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib32"><ce:label>32</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Walaas</ce:surname>
<ce:given-name>S.I.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Greengard</ce:surname>
<ce:given-name>P.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>DARPP-32, a dopamine and adenosine3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. I. Regional and cellular distribution in the rat brain</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurosci.</sb:maintitle>
</sb:title>
<sb:volume-nr>4</sb:volume-nr>
</sb:series>
<sb:date>1984</sb:date>
</sb:issue>
<sb:pages><sb:first-page>84</sb:first-page>
<sb:last-page>98</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib33"><ce:label>33</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Wiesel</ce:surname>
<ce:given-name>F.A.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Sedvall</ce:surname>
<ce:given-name>G.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Post mortal changes of dopamine and homovanillic acid levels in rat striatum as measured by mass fragmentography</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Research</sb:maintitle>
</sb:title>
<sb:volume-nr>65</sb:volume-nr>
</sb:series>
<sb:date>1974</sb:date>
</sb:issue>
<sb:pages><sb:first-page>547</sb:first-page>
<sb:last-page>550</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
<ce:bib-reference id="bib34"><ce:label>34</ce:label>
<sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Zivcovic</ce:surname>
<ce:given-name>B.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Guidotti</ce:surname>
<ce:given-name>A.</ce:given-name>
</sb:author>
<sb:author><ce:surname>Costa</ce:surname>
<ce:given-name>E.</ce:given-name>
</sb:author>
</sb:authors>
<sb:title><sb:maintitle>Effect of neuroleptics on striatal tyrosine hydroxylase: changes in the affinity for the pteridine cofactor</sb:maintitle>
</sb:title>
</sb:contribution>
<sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mol. Pharmacol.</sb:maintitle>
</sb:title>
<sb:volume-nr>10</sb:volume-nr>
</sb:series>
<sb:date>1974</sb:date>
</sb:issue>
<sb:pages><sb:first-page>725</sb:first-page>
<sb:last-page>735</sb:last-page>
</sb:pages>
</sb:host>
</sb:reference>
</ce:bib-reference>
</ce:bibliography-sec>
</ce:bibliography>
</tail>
</article>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man</title>
</titleInfo>
<titleInfo type="alternative" lang="en" contentType="CDATA"><title>Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man</title>
</titleInfo>
<name type="personal"><namePart type="given">R.</namePart>
<namePart type="family">Raisman-Vozari</namePart>
<affiliation>INSERM U 289, CHU Pitie´-Salpeˆtrie`re, Paris France</affiliation>
<description>Correspondence: R. Raisman, Laboratoire de Me´decine Expe´rimentale, INSERM U 289, Hoˆpital de la Salpeˆtrie`re, 47 boulevard de l'Hoˆpital, 75651 Paris Cedex 13, France.</description>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">J.-A.</namePart>
<namePart type="family">Girault</namePart>
<affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10021 U.S.A.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">S.</namePart>
<namePart type="family">Moussaoui</namePart>
<affiliation>INSERM U 318, Laboratoire de Physiologie, Section Neurophysiologie, De´partement des Neurosciences Cliniques et Biologiques, CHU de Grenoble, Grenoble France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">C.</namePart>
<namePart type="family">Feuerstein</namePart>
<affiliation>INSERM U 318, Laboratoire de Physiologie, Section Neurophysiologie, De´partement des Neurosciences Cliniques et Biologiques, CHU de Grenoble, Grenoble France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">P.</namePart>
<namePart type="family">Jenner</namePart>
<affiliation>Parkinson's Disease Society Research Center, University Department of Neurology, Institute of Psychiatry and King's College Hospital Medical School, London U.K.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">C.D.</namePart>
<namePart type="family">Marsden</namePart>
<affiliation>Parkinson's Disease Society Research Center, University Department of Neurology, Institute of Psychiatry and King's College Hospital Medical School, London U.K.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Y.</namePart>
<namePart type="family">Agid</namePart>
<affiliation>INSERM U 289, CHU Pitie´-Salpeˆtrie`re, Paris France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="brief-communication" displayLabel="Short communication"></genre>
<originInfo><publisher>ELSEVIER</publisher>
<dateIssued encoding="w3cdtf">1990</dateIssued>
<copyrightDate encoding="w3cdtf">1990</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="iso639-2b">eng</languageTerm>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
</physicalDescription>
<abstract lang="en">Abstract: The present study was performed to determine the effect of a nearly complete nigrostriatal dopaminergic denervation on DARPP-32 levels in the striatum from animals and parkinsonian patients. DARPP-32 levels were estimated by in vitro phosphorylation in the presence of cAMP, or after inactivation of endogenous kinases and phosphatases, in the presence of the catalytic subunit of cAMP-dependent protein kinase. Intranigral 6-hydroxydopamine (6-OHDA) infusion in rats, or peripheral administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets, did not change striatal DARPP-32 levels. Postmortem studies, carried out on brains obtained shortly after death, from patients with Parkinson disease, or from patients with progressive supranuclear palsy, showed that the levels of striatal DARPP-32 were not different from controls. These results indicate that dopaminergic striatal denervation did not modify the amount of DARPP-32 in the striatum, suggesting that the expression of DARPP-32, a protein which mediates some of the effects of dopamine in striatal neurons, is independent from the dopaminergic innervation.</abstract>
<subject lang="en"><genre>Keywords</genre>
<topic>DARPP-32</topic>
<topic>Tyrosine hydroxylase</topic>
<topic>Phosphoprotein</topic>
<topic>Parkinson</topic>
<topic>Striatum</topic>
<topic>Dopaminergic lesion</topic>
<topic>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Brain Research</title>
</titleInfo>
<titleInfo type="abbreviated"><title>BRES</title>
</titleInfo>
<genre type="journal">journal</genre>
<originInfo><dateIssued encoding="w3cdtf">19900115</dateIssued>
</originInfo>
<identifier type="ISSN">0006-8993</identifier>
<identifier type="PII">S0006-8993(00)X0534-3</identifier>
<part><date>19900115</date>
<detail type="volume"><number>507</number>
<caption>vol.</caption>
</detail>
<detail type="issue"><number>1</number>
<caption>no.</caption>
</detail>
<extent unit="issue pages"><start>1</start>
<end>180</end>
</extent>
<extent unit="pages"><start>45</start>
<end>50</end>
</extent>
</part>
</relatedItem>
<identifier type="istex">FE34E2B9547A365626A3AD65A8E4BEAA74087A3B</identifier>
<identifier type="DOI">10.1016/0006-8993(90)90520-L</identifier>
<identifier type="PII">0006-8993(90)90520-L</identifier>
<identifier type="ArticleID">9090520L</identifier>
<accessCondition type="use and reproduction" contentType="copyright">©1990 Elsevier Science Publishers B.V.</accessCondition>
<recordInfo><recordContentSource>ELSEVIER</recordContentSource>
<recordOrigin>Elsevier Science Publishers B.V., ©1990</recordOrigin>
</recordInfo>
</mods>
</metadata>
</istex>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001444 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001444 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Istex |étape= Corpus |type= RBID |clé= ISTEX:FE34E2B9547A365626A3AD65A8E4BEAA74087A3B |texte= Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |